RGNX Stock Overview
A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
REGENXBIO Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.83 |
| 52 Week High | US$28.80 |
| 52 Week Low | US$10.49 |
| Beta | 1.22 |
| 11 Month Change | -10.57% |
| 3 Month Change | -6.88% |
| 1 Year Change | -38.47% |
| 33 Year Change | -74.28% |
| 5 Year Change | -70.20% |
| Change since IPO | -64.43% |
Recent News & Updates
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Sep 12
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Aug 06Recent updates
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?
Sep 12Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder
Aug 06REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 04Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price
Jul 26Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
Jun 11REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
May 11REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Apr 25Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Mar 11Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers
Mar 07Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified
Mar 05Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 02Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips
Jan 19There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues
Dec 21We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully
Nov 09Will REGENXBIO (NASDAQ:RGNX) Spend Its Cash Wisely?
Aug 08REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 11Here's Why We're Watching REGENXBIO's (NASDAQ:RGNX) Cash Burn Situation
May 08Analysts Are More Bearish On REGENXBIO Inc. (NASDAQ:RGNX) Than They Used To Be
Mar 05Shareholder Returns
| RGNX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.6% | -3.8% | 1.8% |
| 1Y | -38.5% | 16.5% | 31.9% |
Return vs Industry: RGNX underperformed the US Biotechs industry which returned 18.7% over the past year.
Return vs Market: RGNX underperformed the US Market which returned 32.8% over the past year.
Price Volatility
| RGNX volatility | |
|---|---|
| RGNX Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGNX's share price has been volatile over the past 3 months.
Volatility Over Time: RGNX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 344 | Curran Simpson | www.regenxbio.com |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
REGENXBIO Inc. Fundamentals Summary
| RGNX fundamental statistics | |
|---|---|
| Market cap | US$554.03m |
| Earnings (TTM) | -US$241.08m |
| Revenue (TTM) | US$89.04m |
6.0x
P/S Ratio-2.2x
P/E RatioIs RGNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGNX income statement (TTM) | |
|---|---|
| Revenue | US$89.04m |
| Cost of Revenue | US$265.81m |
| Gross Profit | -US$176.76m |
| Other Expenses | US$64.31m |
| Earnings | -US$241.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.88 |
| Gross Margin | -198.51% |
| Net Profit Margin | -270.74% |
| Debt/Equity Ratio | 21.0% |
How did RGNX perform over the long term?
See historical performance and comparison